Heparin joins cells at a site adjacent to ACE2, the portal for SARS-CoV-2 infection, and “powerfully” blocks the virus, which can open up remedy options.
The biggest focus on postviral effects is what’s new in persistent heart injuries after COVID-19, suggests an article in The Atlantic.
Nearly 2% of patients with COVID-19 suffer from stroke, with “extremely high” hospital mortality of 34%, a meta-analysis (Neurology).
Opportunistic screening for atrial traumatic inflammation (Afib) at number one care visits of the elderly did not actually increase the detection rate in a randomized pragmatic trial in the Netherlands (The BMJ).
Johns Hopkins Hospital has remodeled its interactive game room for stroke rehabilitation in a decompression area for staff in the COVID-19 lockdown.
Post-IM effects improved, for women, from 2008 to 2017. (Circulation)
September 21 marked the 60th anniversary of the first successful mitral valve implant (The Oregonian).
James T. Willerson, MD, “a cardiology giant,” died last week at the age of 81. (Cardiovascular Business)
Non-automatic telephone triage systems used outdoors during working hours underestimated the emergency in 27% of patients with acute coronary syndrome or other life-threatening events (open heart).
The threat of occasions related to cumulative exposure to higher cholesterol suggests that it would possibly be preferable to interfere before middle age and think of “years of cholesterol” than “package years” of smoking. (Journal of the American College of Cardiology [JACC] )
Patients with black center failure had a worse diagnosis than their white peers even after assembling NT-proBNP-based remedy targets, according to a Circulation study.
The rest of the intra-stent has made significant progress with the new stents that circumvent the drug, but it still occurs in a “considerable proportion” of patients (JACC).
The understanding that the disease of the center is the leading cause of death among women decreased from 2009 to 2019, between minorities and young women (Circulation).
Tyrx’s resorbable antibacterial envelope for implantable heart devices can be cost effective at $112,603 according to the quality-adjusted year of life (Circulation: arrhythmia and electrophysiology).
The second generation AcQMap 3-d imaging and mapping catheter has been approved by the FDA, Acutus Medical announced.
Abbott said his next-generation MitraClip G4 had received approval from European regulators.
The British National Institute for Excellence in Health and Care has issued positive advice for aralsorsen (Waylivra) as a remedy for family chemomicronemia syndrome, Akcea announced.
Adaptive cardiac resynchronization (CKD) treatment is no greater than traditional CKD for electrical dyssynchrony in a small check reported on the medRxiv prepress server.
Mobile exosomes from human-induced pluripotent centers advanced the recovery of IM in pigs (BioWorld)
Crystal Phend focuses on cardiology as an editor at MedPage Today.
At MedPage Today, we are committed to ensuring that other people with disabilities can access all the content MedPage Today has to do through our online page and other properties. send an email to legal@ziffdavis. com for help. Type “ADA Request” in the thematic line of your email.